Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit

British Journal of Pharmacology

Volumn 164, Issue 2 B, 2011, Pages 561-569

  Kaber, G ^a   Kaiser, B ^b   Baumgartel Allekotte D ^a   Rauch, B H ^a   Nossmann S ^b   Heim, K H ^c   Weber, A A ^d   Nagy, N ^a   Fischer, J W ^a   Schror K ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

^d University Clinic   (Germany)

Author keywords

acetylsalicylic acid; atherosclerosis; cyclo oxygenase; prostacyclin; rofecoxib; thromboxane

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CYCLOOXYGENASE 2; PROSTACYCLIN; PROSTAGLANDIN E2; ROFECOXIB; THROMBOXANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIATHEROSCLEROTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT LYSIS; CHOLESTEROL DIET; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG ANTAGONISM; ENZYME INHIBITION; EXPERIMENTAL RABBIT; FEMALE; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOGENESIS; THROMBOSIS;

ANIMAL FEED; ANIMALS; AORTA; ASPIRIN; ATHEROSCLEROSIS; CHOLESTEROL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DRUG ANTAGONISM; EPOPROSTENOL; FEMALE; FIBRINOLYTIC AGENTS; IMMUNOHISTOCHEMISTRY; LACTONES; MALE; PLATELET AGGREGATION INHIBITORS; RABBITS; SULFONES; THROMBOSIS; THROMBOXANES;

EID: 80052212306     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01392.x     Document Type: Article

References (38)

1. Babaev VR, Ding L, Reese J, Morrow JD, Breyer MD, Dey SK, et al,. (2006). Cyclooxygenase-1 deficiency in bone marrow cells increases early atherosclerosis in apolipoprotein E- and low-density lipoprotein receptor-null mice. Circulation 113: 108-117. (Pubitemid 43958495)
2. Barrett PA, Butler KD, (1983). Shortening of platelet survival by induced hypercholesterolaemia in rabbits and its prolongation by anagrelide. Thromb Haemost 50: 656-659. (Pubitemid 14241253)
3. Bea F, Blessing E, Bennett BJ, Kuo CC, Campbell LA, Kreuzer J, et al,. (2003). Chronic inhibition of cyclooxygenase-2 does not alter plaque composition in a mouse model of advanced unstable atherosclerosis. Cardiovasc Res 60: 198-204. (Pubitemid 38373492)
4. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ, (2000). Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 102: 840-845.
5. Belton OA, Duffy A, Toomey S, Fitzgerald DJ, (2003). Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108: 3017-3023. (Pubitemid 37553572)
6. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al,. (2002). Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105: 1816-1823. (Pubitemid 34408892)
7. Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, et al,. (2005). Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol 39: 443-452. (Pubitemid 41133730)
8. Butler KD, Butler PA, Shand RA, Ambler J, Wallis RB, (1987). Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. Thromb Res 45: 751-761. (Pubitemid 17053696)
9. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al,. (2001). Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817.
10. Cheng Y, Austin SC, Rocca B, Koller BH, Coffman TM, Grosser T, et al,. (2002). Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541. (Pubitemid 34408674)
11. Egan KM, Wang M, Fries S, Lucitt MB, Zukas AM, Pure E, et al,. (2005). Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111: 334-342. (Pubitemid 40165341)
12. FitzGerald GA, (2003). COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2: 879-890.
13. Fitzgerald GA, (2004). Coxibs and cardiovascular disease. N Engl J Med 351: 1709-1711.
14. FitzGerald GA, Smith B, Pedersen AK, Brash AR, (1984). Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310: 1065-1068. (Pubitemid 14131497)
15. Folts J, (1991). An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 83 (6 Suppl.): IV3-I14.
16. Folts JD, Crowell EB, Jr, Rowe GG, (1976). Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 54: 365-370.
17. Hennan JK, Huang J, Barrett TD, Driscoll EM, Willens DE, Park AM, et al,. (2001). Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820-825. (Pubitemid 32762682)
18. Hohlfeld T, Zimmermann N, Weber AA, Jessen G, Weber H, Schrör K, et al,. (2008). Pyrazolinone analgesics prevent the antiplatelet effect of aspirin and preserve human platelet thromboxane synthesis. J Thromb Haemost 6: 166-173.
19. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA, (1998). Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 97: 716-720. (Pubitemid 28135332)
20. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M, (2004). Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 364: 2021-2029. (Pubitemid 39593078)
21. Kharbanda RK, Walton B, Allen M, Klein N, Hingorani AD, MacAllister RJ, et al,. (2002). Prevention of inflammation-induced endothelial dysfunction: a novel vasculo-protective action of aspirin. Circulation 105: 2600-2604. (Pubitemid 34596035)
22. Livio M, Del Maschio A, Cerletti C, de Gaetano G, (1982). Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 23: 787-796. (Pubitemid 13238162)
23. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA, (1999). Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 96: 272-277. (Pubitemid 29036089)
24. Mitchell JA, Lucas R, Vojnovic I, Hasan K, Pepper JR, Warner TD, (2006). Stronger inhibition by nonsteroid anti-inflammatory drugs of cyclooxygenase-1 in endothelial cells than platelets offers an explanation for increased risk of thrombotic events. FASEB J 20: 2468-2475. (Pubitemid 44953819)
25. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, et al,. (1995). Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 83: 473-482.
26. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al,. (2005). Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091. (Pubitemid 40365349)
27. Olesen M, Kwong E, Meztli A, Kontny F, Seljeflot I, Arnesen H, et al,. (2002). No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand Cardiovasc J 36: 362-367. (Pubitemid 36131423)
28. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA, (1987). Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis 68: 231-240. (Pubitemid 17159775)
29. Patrignani P, Panara MR, Greco A, Fusco O, Natoli C, Lacobelli S, et al,. (1994). Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 271: 1705-1712. (Pubitemid 24382690)
30. Pedersen AK, FitzGerald GA, (1984). Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311: 1206-1211. (Pubitemid 14021923)
31. Prasad K, Lee P, (2003). Suppression of oxidative stress as a mechanism of reduction of hypercholesterolemic atherosclerosis by aspirin. J Cardiovasc Pharmacol Ther 8: 61-69. (Pubitemid 36363212)
32. Pratico D, Tillmann C, Zhang ZB, Li H, FitzGerald GA, (2001). Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci USA 98: 3358-3363. (Pubitemid 32220850)
33. Rao GH, Johnson GG, Reddy KR, White JG, (1983). Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 3: 383-388. (Pubitemid 13030926)
34. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB, (1994). Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb 14: 1021-1031.
35. Rott D, Zhu J, Burnett MS, Zhou YF, Zalles-Ganley A, Ogunmakinwa J, et al,. (2003). Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J Am Coll Cardiol 41: 1812-1819. (Pubitemid 36584257)
36. Schrör K, Seidel H, (1988). Blood-vessel wall arachidonate metabolism and its pharmacological modification in a new in vitro assay. Naunyn Schmiedebergs Arch Pharmacol 337: 177-182. (Pubitemid 18076716)
37. Van Hecken A, Schwartz JI, Depre M, De Lepeleire I, Dallob A, Tanaka W, et al,. (2000). Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 1109-1120.
38. Wang T, Falardeau P, Powell WS, (1991). Synthesis of prostaglandins and thromboxane B2 by cholesterol-fed rabbits. Arterioscler Thromb 11: 501-508.